Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
reMYND NV (‘reMYND’) announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in early stage drug discovery.
RadarScreen allows high-throughput identification of genotoxic liabilities, such as the induction of chromosomal breaks and DNA mutations, of compounds and their corresponding metabolites. It is a yeast-based technology comprising a fast, reproducible and highly robust enzymatic assay for cost-effective screening in a standard laboratory environment. In contrast with currently available tests, these characteristics permit extensive genotoxicity assessments early in the development process, already at the hit identification stage. As such RadarScreen provides guidance to chemical optimization and may prevent later stage failures. reMYND has developed and validated RadarScreen over the past few years and is licensing-out this technology to the pharma, biotech, food, environmental, cosmetics and chemical industries. reMYND is currently also developing ready-to-use kits in the form of 384-well-plates in collaboration with BioPredic International, based in France.
According to An Tanghe, reMYND’s Business Developer, “RadarScreen has been developed by reMYND’s scientists to address a clear need: the ability to screen for genotox liabilities early in reMYND’s own drug discovery process. The promising validation data obtained in-house and at Schering-Plough have triggered the decision to out-license the technology. Schering-Plough has been using RadarScreen for one year now and we are delighted about their enthusiasm. I have a firm belief, though, that not only the pharmaceutical industry can benefit from using RadarScreen. There are ample other industries for which elimination of genotoxic compounds at an early stage is essential, for instance food, environmental and cosmetics. Moreover, RadarScreen can play a pivotal role in helping the chemical industry to comply with the recently introduced REACH-legislation that gives greater responsibility to industry to manage the risks from chemicals and provide safety information on the substances “
Source: reMYND
Tags: alliances
Bookmark this:
